HOME >> MEDICINE >> NEWS
New compound holds promise for lupus and related diseases

Ann Arbor, MI A chemical cousin of anti-anxiety medications, such as Valium and Xanax, significantly reduces kidney inflammation in mice inbred to develop a disease resembling human systemic lupus erythematosus (SLE), researchers at the University of Michigan and the University of California-Berkeley have found.

Their research, described in the Oct. 16 issue of the Journal of Clinical Investigation, also reveals the novel mechanism by which the compound works, a discovery that could lead to safer and more effective new drugs for managing lupus and other autoimmune disorders.

"The best available therapies for lupus haven't changed for many, many years," says U-M's Gary D. Glick, Ph.D., one of the lead authors on the study. "It's a disease where the mechanisms that normally prevent the immune system from attacking components of one's own body are defective. Because we do not yet understand what triggers lupus, it has been very difficult to develop lupus-specific therapies."

In fact, the mainstays of treating lupus-related kidney inflammation---the major cause of illness and death in lupus patients---are drugs developed many years ago to kill cancer cells. When given to lupus patients, often in combination with immune-suppressing steroids, these cytotoxic agents kill immune cells. But because they lack specificity, they also kill healthy cells, resulting in serious side effects. What's more, they simply are not effective in some patients.

"Our compound, on the other hand, goes in and kills the bad players but leaves the good players alone," says Glick, a charter faculty member of the U-M Life Sciences Institute, who is the Werner E. Bachmann Collegiate Professor of Chemistry, and a professor of biological chemistry in the U-M Medical School.

The compound, a 1,4-benzodiazepine (designated as Bz-423), sets off a chain of events that results in apoptosis, a natural cell-suicide process by which the body rids itself of cells
'"/>

Contact: Sally Pobojewski
pobo@umich.edu
734-615-6912
University of Michigan Health System
16-Oct-2002


Page: 1 2 3

Related medicine news :

1. New compounds effective against Alzheimers disease onset and progression
2. Marijuana-like compounds may aid array of debiliating conditions ranging from Parkinsons to pain
3. New compounds show promise in fighting malaria and cancer
4. Blueberry compound shows promise of lowering cholesterol as effectively as drug
5. New class of compounds promises to revive failing hearts
6. New compound may act to keep thyroid activity in check
7. Study finds certain compounds in beer, wine effective in slowing breast cancer cell growth
8. Researchers testing compounds that may stop replication of T-cell leukemia virus
9. Cocoa froths with cancer-preventing compounds
10. Alcohol may compound its damaging effects through frontocerebellar circuitry
11. Synthetic marijuana compound reduces agitation, improves appetite in Alzheimers patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/20/2017)... ... February 20, 2017 , ... A new digital ... are called back for additional examinations without sacrificing cancer detection, according to a ... the U.S. Food and Drug Administration approved digital breast tomosynthesis (DBT) for use ...
(Date:2/20/2017)... VA (PRWEB) , ... February 20, 2017 , ... Silverado ... Cambridge Healthcare to open and operate a state-of-the-art memory care community in Alexandria, Virginia. ... 2018 on a site just outside of Old Town. , The three-story community ...
(Date:2/20/2017)... ... February 20, 2017 , ... Clearwave is the ... on the Posiflex XT-series of touch screen terminals. Both companies will be showcasing ... Florida. The terminal provider Posiflex is helping to bridge the gap between healthcare ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... as an employee health benefit for companies that want to help members of ... providers, employees will have access to Watson’s suite of oncology offerings for insights ...
(Date:2/20/2017)... ... February 20, 2017 , ... Chuck E. Cheese’s® and ... Sundays, a joint event at Chuck E. Cheese’s locations throughout New England, New York ... needs, the opportunity to experience the fun of visiting Chuck E. Cheese’s in a ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... Feb. 21, 2017 Research and Markets has announced ... 2016" report to their offering. ... The latest research Rosacea Drugs Price Analysis and Strategies - ... The research answers the following questions: ... How are they positioned in the Global Rosacea market? ...
(Date:2/20/2017)... Taiwan , Feb. 21, 2017 Taiwan ... leading provider of non-invasive vital signs sensing solutions, today ... industry,s first finger-free wrist pulse oximeter, the oCare TM ... the wearable healthcare and medical devices space.  ... 100, provides a non-invasive, simple and reliable method to ...
(Date:2/20/2017)...  This Report analyzes the worldwide markets for Pharmaceutical Contract Manufacturing ... Forms, and Liquid & Semi-solid Dosage Forms. The report provides separate ... Japan , Europe , ... the full report: http://www.reportlinker.com/p04707109-summary/view-report.html ... Annual estimates and forecasts are provided for ...
Breaking Medicine Technology:
Cached News: